COX-2 inhibitors significantly reduce risk of cancer ( Results from a new five-year study sho...)

COX-2 inhibitors significantly reduce risk of cancer

Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.

The study findings were released today at the annual meeting of the American Association for Cancer Research in Washington, D.C.

"We believe this is the first study to show that selective COX-2 inhibitors have significant chemopreventive effects against breast cancer," says Dr. Randall Harris, professor and director of the Center for Molecular Epidemiology and Environmental Health in The Ohio State University College of Medicine and lead author of the study.

The results come from a larger, case-control study of NSAID use and its impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. NSAIDs are non-steroidal, anti-inflammatory drugs that block the COX-2 enzyme pathway that is often activated in inflammation, cancer, heart disease and other disorders.

Harris and his colleagues studied the use of celecoxib (Celebrex), rofecoxib (Vioxx), regular aspirin, low-dose aspirin, ibuprofen and acetaminophen among 323 women with breast cancer from 1999-2004.

They compared the results with those from a control group of 649 cancer-free women matched for age, race and county of residence.

They discovered that women who used NSAIDs on a regular basis had less breast cancer. Specifically, they found that those who used celecoxib or rofecoxib for at least two years appeared to benefit the most, experiencing a 71 percent reduction in risk of breast cancer. Ibuprofen use over the same period was associated with a 64 percent reduction, while regular aspirin offered a 51 percent reduction in risk of the disease.

On the other hand, acetaminophen, which has a negligible effect upon COX-2 activity, and low-dose aspirin provided no significant ch
'"/>

Source:Ohio State University Medical Center

Page: 1 2
Related biology news :

1. New understanding of COX-1 and COX-2 enzymes could revise classification of pain meds
2. Anthrax inhibitors identified by Burnham team
3. Protease inhibitors reach beyond HIV
4. Enzyme inhibitors block replication of SARS virus
5. Sweet water taste paradoxically predicts sweet taste inhibitors
6. High HPV concentrations combined with smoking significantly raise risks of cervical cancer
7. Male circumcision reduces risk of HIV transmission from women to men
8. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
9. Use of PET can reduce, may eliminate more strenuous drug development trials with animals
10. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
11. Physiological effects of reduced gravity on bacteria

Post Your Comments:

( Results from a new five-year study sho...)COX-2 inhibitors significantly reduce risk of cancer